Compare ALIT & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALIT | ABEO |
|---|---|---|
| Founded | 2017 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 394.4M | 399.5M |
| IPO Year | 2020 | 2005 |
| Metric | ALIT | ABEO |
|---|---|---|
| Price | $8.95 | $5.05 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $17.00 | ★ $18.88 |
| AVG Volume (30 Days) | 399.1K | ★ 1.3M |
| Earning Date | 11-04-2026 | 11-11-2026 |
| Dividend Yield | ★ 8.97% | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,262,000,000.00 | $2,998,000.00 |
| Revenue This Year | N/A | $804.33 |
| Revenue Next Year | N/A | $119.68 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $0.48 | $4.00 |
| 52 Week High | $23.68 | $7.65 |
| Indicator | ALIT | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 28.18 | 35.55 |
| Support Level | $0.56 | $4.94 |
| Resistance Level | $15.32 | $5.46 |
| Average True Range (ATR) | 0.75 | 0.21 |
| MACD | -0.31 | -0.01 |
| Stochastic Oscillator | 1.15 | 11.39 |
Alight Inc is a technology-enabled services company delivering human capital management solutions to many complex organizations. This includes the implementation and administration of employee benefits (e.g., health, wealth, and leave benefits) solutions, which currently operate under one reportable segment, Employer Solutions. The Employer Solutions segment is driven by the Alight Worklife platform, and includes integrated benefits administration, healthcare navigation, financial well-being, leave of absence management, and retiree healthcare. Geographically, the company generates the majority of its revenue from the United States.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.